Dual Modulation of ERK1/2 and p38 MAP Kinase Activities Induced by Minocycline Reverses the Neurotoxic Effects of the Prion Protein Fragment 90–231

[1]  David R. Brown,et al.  Resistance of cell lines to prion toxicity aided by phospho‐ERK expression , 2008, Journal of neurochemistry.

[2]  G. Forloni,et al.  The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection , 2008, PloS one.

[3]  J. Bussink,et al.  Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. , 2008, The Lancet. Oncology.

[4]  S. Mok,et al.  Evaluation of drugs for treatment of prion infections of the central nervous system. , 2008, The Journal of general virology.

[5]  Wei Liu,et al.  A novel role of minocycline: Attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia , 2008, Brain, Behavior, and Immunity.

[6]  A. Aceto,et al.  Intracellular accumulation of a mild‐denatured monomer of the human PrP fragment 90–231, as possible mechanism of its neurotoxic effects , 2007, Journal of neurochemistry.

[7]  H. Kretzschmar,et al.  Different structural stability and toxicity of PrPARR and PrPARQ sheep prion protein variants , 2007, Journal of neurochemistry.

[8]  A. Aceto,et al.  ERK1/2 and p38 MAP kinases control prion protein fragment 90–231‐induced astrocyte proliferation and microglia activation , 2007, Glia.

[9]  I. Zerr,et al.  Therapeutic approaches for prion disorders , 2007, Expert review of anti-infective therapy.

[10]  J. Grosclaude,et al.  In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers , 2007, PLoS pathogens.

[11]  A. Aguzzi,et al.  Insights into prion strains and neurotoxicity , 2007, Nature Reviews Molecular Cell Biology.

[12]  N. Bhat,et al.  p38α MAP Kinase Mediates Hypoxia-Induced Motor Neuron Cell Death: A Potential Target of Minocycline’s Neuroprotective Action , 2007, Neurochemical Research.

[13]  David R. Brown,et al.  Modelling neurodegeneration in prion disease – applications for drug development , 2007, Expert opinion on drug discovery.

[14]  A. Aceto,et al.  Amino‐Terminally Truncated Prion Protein PrP90‐231 Induces Microglial Activation in Vitro , 2007, Annals of the New York Academy of Sciences.

[15]  E. Langella,et al.  Does tetracycline bind helix 2 of prion? An integrated spectroscopical and computational study of the interaction between the antibiotic and α helix 2 human prion protein fragments , 2006, Proteins.

[16]  A. Aceto,et al.  Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231. , 2006, Annals of the New York Academy of Sciences.

[17]  J. Collinge,et al.  A systematic review of prion therapeutics in experimental models. , 2006, Brain : a journal of neurology.

[18]  A. Aguzzi.  Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis , 2006, Journal of neurochemistry.

[19]  A. Aceto,et al.  Conformation Dependent Pro-Apoptotic Activity of the Recombinant Human Prion Protein Fragment 90-231 , 2006, International journal of immunopathology and pharmacology.

[20]  P. Peters,et al.  Emerging pharmacotherapies for Creutzfeldt-Jakob disease. , 2006, Archives of neurology.

[21]  J. Steeves,et al.  Minocycline as a Neuroprotective Agent , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[22]  M. Duddy,et al.  Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. , 2005, The Journal of infection.

[23]  C. Power,et al.  For Personal Use. Only Reproduce with Permission from Elsevier Ltd Minocycline and Neurological Diseases Minocycline in Animal Models the Promise of Minocycline in Neurology , 2022 .

[24]  Ming-tao Li,et al.  Minocycline prevents glutamate‐induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways , 2004, Journal of neurochemistry.

[25]  A. Sobel,et al.  Clustering of cellular prion protein induces ERK1/2 and stathmin phosphorylation in GT1‐7 neuronal cells , 2004, FEBS letters.

[26]  P. Caplazi,et al.  Resistance to scrapie in PrP ARR/ARQ heterozygous sheep is not caused by preferential allelic use , 2004, Journal of Clinical Pathology.

[27]  D. Hess,et al.  Minocycline Up-regulates Bcl-2 and Protects against Cell Death in Mitochondria* , 2004, Journal of Biological Chemistry.

[28]  M. Salmona,et al.  Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity* , 2004, Journal of Biological Chemistry.

[29]  D. Hess,et al.  Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection , 2004, Experimental Neurology.

[30]  E. Irle,et al.  Efficacy of flupirtine on cognitive function in patients with CJD , 2004, Neurology.

[31]  M. E. Eichler,et al.  Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Tatsuo Yamada,et al.  Results of Quinacrine Administration to Patients with Creutzfeldt-Jakob Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[33]  G. Damonte,et al.  Prion Protein Fragment 106–126 Induces a p38 MAP Kinase—Dependent Apoptosis in SH‐SY5Y Neuroblastoma Cells Independently from the Amyloid Fibril Formation , 2003, Annals of the New York Academy of Sciences.

[34]  Carla Perrone-Capano,et al.  Chronic activation of ERK and neurodegenerative diseases , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  J. Castilla,et al.  Caspase‐12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein , 2003, The EMBO journal.

[36]  G. Forloni,et al.  Prion Diseases: Time for a Therapy ? , 2003 .

[37]  G. Damonte,et al.  Contribution of two conserved glycine residues to fibrillogenesis of the 106–126 prion protein fragment. Evidence that a soluble variant of the 106–126 peptide is neurotoxic , 2003, Journal of neurochemistry.

[38]  G. Forloni,et al.  Tetracyclines affect prion infectivity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Damonte,et al.  Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein , 2002, Neurochemistry International.

[40]  G. Damonte,et al.  p38 MAP Kinase Mediates the Cell Death Induced by PrP106–126 in the SH-SY5Y Neuroblastoma Cells , 2002, Neurobiology of Disease.

[41]  T. Cotter,et al.  Prion Protein Fragment PrP-(106–126) Induces Apoptosis via Mitochondrial Disruption in Human Neuronal SH-SY5Y Cells* , 2001, The Journal of Biological Chemistry.

[42]  S. Prusiner,et al.  Shattuck lecture--neurodegenerative diseases and prions. , 2001, The New England journal of medicine.

[43]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[44]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[45]  G. Forloni,et al.  Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.

[46]  G. Forloni,et al.  Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106–126 , 2000, International Journal of Developmental Neuroscience.

[47]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[48]  M. Comalada,et al.  The Differential Time-course of Extracellular-regulated Kinase Activity Correlates with the Macrophage Response toward Proliferation or Activation* , 2000, The Journal of Biological Chemistry.

[49]  O. Khorkova,et al.  α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation , 1998 .

[50]  J Collinge,et al.  Human prion diseases and bovine spongiform encephalopathy (BSE). , 1997, Human molecular genetics.

[51]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[52]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[53]  R J Fletterick,et al.  Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Aguzzi,et al.  Approaches to therapy of prion diseases. , 2005, Annual review of medicine.

[55]  J. Collinge.  Prion diseases of humans and animals: their causes and molecular basis. , 2001, Annual review of neuroscience.

[56]  O. Khorkova,et al.  Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  E. Nånberg,et al.  Differentiation and survival influences of growth factors in human neuroblastoma. , 1995, European journal of cancer.